Table 1 Demographic and clinicopathological data of all participants

Gender (male/female)

19/6

21/4

24/1

Age (years)

42.48 ± 8.39

40.08 ± 10.43

36.32 ± 11.67

BMI (kg/m²)

23.07 ± 1.68

29.24 ± 4.80^c

26.65 ± 4.40^a

SBP (mmHg)

118.6 ± 4.7

147.5 ± 9.4^c

193.8 ± 19.0^a,b

DBP (mmHg)

79.88 ± 4.02

92.00 (90.00–100.00)^c

114.36 ± 14.33^a,b

Uric acid

274.84 ± 59.69

503.92 ± 116.81^c

508.56 ± 120.21^a

BUN (mmol/L)

5.17 ± 1.64

7.53 ± 3.10

15.52 (12.15–22.89)^a,b

Scr (μmol/L)

59.25 ± 11.37

132.00 (103.50–180.50)^c

390.00 (237.00–546.50)^a,b

eGFR (mL/min/1.73 m²)

118.60 ± 22.74

57.67 ± 30.06^c

17.00 (8.20–30.00)^a,b

Elabela (ng/ml)

6.29 ± 0.94

4.73 ± 1.25^c

3.82 ± 1.08^a,b

Histopathological

 TAIF

–

1.88 ± 0.78

2.63 ± 0.71

 Intimal fibrosis

–

1.00(1.00, 2.00)

2.00(2.00, 2.00)

 Fibrinoid necrosis, n (%)

–

0

9 (62.5)

 Myointimal cell proliferation, n (%)

–

0

22 (91.7)